Prescribing Appropriateness of Thrombo-prophylaxis in Intensive Care Unit of Tertiary Hospital

Pattern of Prescribing Anticoagulants As DVT Prophylaxis in Intensive Care Unit of Tertiary Hospital

Hospitalized patients are at high risk of venous thromboembolism (VTE), and the appropriate use of thromboprophylaxis can significantly reduce the incidence of VTE in high-risk patients. We investigated the pattern of VTE prophylaxis administration among elderly medical patients and assessed its appropriateness based on the American College of Chest Physicians (ACCP) recommendations. Methods A cross-sectional single-center study will be conducted between July 2024 and December 2024, including hospitalized (> 48 h), (≥ 60 years), medical and surgical patients, and excluding patients receiving anticoagulant for other reason, having contraindication to thromboprophylaxis, or had VTE diagnosed within 48 h. The Padua and caprine prediction scores will be used to determine the patients' risk for VTE, and thromboprophylaxis use will be assessed against the ACCP recommendations.

Study Overview

• Status: Completed
• Conditions: DVT
• Intervention / Treatment: Other: DVT prophyllaxis

• Study Type: Observational
• Enrollment (Actual): 400

Contacts and Locations

Study Locations

• Egypt
  • Cairo, Egypt, 4270020
    • Teachers Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patient records admitted to the ICU with medical or surgical causes treated with anticoagulants for DVT prophylaxis will be collected Patients already on anticoagulant therapy, had history of previous DVT, had End-stage liver disease, admitted with hemorrhage/bleeding or not prescribed DVT prophylaxis will be excluded.

Description

Inclusion Criteria:

Patient records

• admitted to the ICU with
• medical or surgical causes
• recieved anticoagulants for DVT prophylaxis

Exclusion Criteria:

• Patients already on anticoagulant therapy,
• had history of previous DVT,
• had End-stage liver disease,
• admitted with hemorrhage/bleeding
• not prescribed DVT prophylaxis

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Surgical Patients	Other: DVT prophyllaxis; VTE prophylaxis administration among patients based on the American College of Chest Physicians (ACCP) recommendations
Medical Patients	Other: DVT prophyllaxis; VTE prophylaxis administration among patients based on the American College of Chest Physicians (ACCP) recommendations

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Padua score for medical patients	Venous thromboembolism Risk assessment (Scores 0-3 are low risk and do not warrant prophylaxis. Scores ≥4 are high risk for VTE and subsequent complications; recommendation for thromboprophylaxis.)	within 24 hours of ICU admission
Caprini score for surgical patients	Venous thromboembolism Risk assessment (Total score of 0-1: Low risk of VTE Total score of ≥3: High/moderate risk of VTE )	within 24 hours of ICU admission

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bleeding risk assessment		within 24 hours of ICU admission
Direct Anticoagulant cost	sum of costs related to the anticoagulant administration for DVT Prophylaxis	within 24 hours of ICU admission till ICU discharge(at least 48 hours)
Adverse drug reaction cost	sum of costs related to the Adverse drug reaction for DVT Prophylaxis	within 24 hours of ICU admission till ICU discharge (at least 48 hours)

Collaborators and Investigators

• Sponsor: Ain Shams University
• Collaborators: Egyptian Chinese University; Teachers Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2024
• Primary Completion (Actual): December 1, 2024
• Study Completion (Actual): December 1, 2024

Study Registration Dates

• First Submitted: July 29, 2024
• First Submitted That Met QC Criteria: August 2, 2024
• First Posted (Actual): August 6, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 24, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: 2887764466

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No